anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults
1. Aged 80 and over 80+ years 2. Terminal Illness 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Dyspnea 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Chronic Heart Failure 5. Acquired Immunodeficiency Syndrome 6. Young Adult 19-24 years 7. Chronic Obstructive Pulmonary Disease 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Cancer
Provide patient population that should be included in the study
Laparoscopy versus laparotomy for FIGO stage I ovarian cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Ovarian Cancer Stage I 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Exercise for women receiving adjuvant therapy for breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Chemotherapy 4. Middle Aged 45-64 years 5. Adjuvant Therapy 6. Young Adult 19-24 years 7. Radiotherapy 8. Breast Cancer 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Therapeutic exercises for affecting post‐treatment swallowing in people treated for advanced‐stage head and neck cancers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Squamous Cell Carcinoma Of Head And Neck 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Dysphagia 7. Head and Neck Therapeutic Procedures 8. Aged 65-79 years
Provide patient population that should be included in the study
Nutritional interventions for survivors of childhood cancer
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Chemotherapy 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Radiotherapy 10. Adolescent 13-18 years 11. Cancer
Provide patient population that should be included in the study
Non‐pharmacological interventions for cognitive impairment due to systemic cancer treatment
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Chemotherapy 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Cancer 9. Hormone Therapy
Provide patient population that should be included in the study
Interventions for treating oral leukoplakia to prevent oral cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Leukoplakia Of Oral Mucosa 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Sun protection for preventing basal cell and squamous cell skin cancers
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Molecular‐targeted first‐line therapy for advanced gastric cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Adenocarcinoma Of Stomach 5. Young Adult 19-24 years 6. Adenocarcinoma Of Esophagus 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Cervical Intraepithelial Neoplasia Grade 1 4. Middle Aged 45-64 years 5. Surgery 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Hypofractionated radiation therapy for early breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Breast Conserving Surgery 5. Young Adult 19-24 years 6. Early Breast Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Intracystic bleomycin for cystic craniopharyngiomas in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Craniopharyngioma 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer
1. Aged 80 and over 80+ years 2. Ovarian Cancer 3. Adult 19-44 years 4. Relapse 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Radiotherapy for diffuse brainstem glioma in children and young adults
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Glioma Of Brainstem 4. Infant 1 to 23 mo 5. Young Adult 19-24 years 6. Birth to 1 mo 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Massage with or without aromatherapy for symptom relief in people with cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Cancer
Provide patient population that should be included in the study
Follow‐up strategies for women treated for early breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Breast Conserving Surgery 5. Young Adult 19-24 years 6. Early Breast Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
High‐dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Chemotherapy 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Breast Cancer 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Different types of implants for reconstructive breast surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Radical Mastectomy 5. Young Adult 19-24 years 6. Breast Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pancreaticoduodenectomy 6. Aged 65-79 years
Provide patient population that should be included in the study
Non‐surgical interventions for late rectal problems (proctopathy) of radiotherapy in people who have received radiotherapy to the pelvis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Radiation Proctopathy 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Neutropenic Disorder 6. Chemotherapy 7. Middle Aged 45-64 years 8. Infant 1 to 23 mo 9. Young Adult 19-24 years 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Cancer
Provide patient population that should be included in the study
Oral morphine for cancer pain
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Cancer Pain 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Chromoscopy versus conventional endoscopy for the detection of polyps in the colon and rectum
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Endoscopy 6. Aged 65-79 years
Provide patient population that should be included in the study
Ganoderma lucidum (Reishi mushroom) for cancer treatment
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Biopsy 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Cancer
Provide patient population that should be included in the study
Laparoscopic versus open distal pancreatectomy for pancreatic cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Pancreatic ductal adenocarcinoma. 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Laparoscopic versus open gastrectomy for gastric cancer
1. Aged 80 and over 80+ years 2. Adenocarcinoma gastric 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Dyspnea 5. Young Adult 19-24 years 6. Terminal Illness - Late Stage 7. Advanced Cancer 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Laparoscopic versus open transhiatal oesophagectomy for oesophageal cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Esophageal Cancer 6. Aged 65-79 years
Provide patient population that should be included in the study
Physical exercise training interventions for children and young adults during and after treatment for childhood cancer
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Young Adult 19-24 years 5. Birth to 1 mo 6. Recurrence free survival 7. Adolescent 13-18 years 8. Cancer
Provide patient population that should be included in the study
Non‐surgical versus surgical treatment for oesophageal cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Esophageal Cancer 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Very early discharge versus early discharge versus non‐early discharge in children with cancer and febrile neutropenia
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Febrile Neutropenia 5. Young Adult 19-24 years 6. Birth to 1 mo 7. Adolescent 13-18 years 8. Cancer
Provide patient population that should be included in the study
Pylorus‐preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma
1. Pancreatic carcinoma
Provide patient population that should be included in the study
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Metastatic Colorectal Cancer 5. Infant 1 to 23 mo 6. Colorectal Cancer 7. Advanced Cancer 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Adult 19-44 years 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
End‐of‐life care pathways for improving outcomes in caring for the dying
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Terminal Illness - Late Stage 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Percutaneous endoscopic gastrostomy versus percutaneous radiological gastrostomy for swallowing disturbances
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Difficulty Swallowing 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Antiemetic medication for prevention and treatment of chemotherapy‐induced nausea and vomiting in childhood
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Chemotherapy 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Adolescent 13-18 years 7. Cancer
Provide patient population that should be included in the study
Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer
1. Aged 80 and over 80+ years 2. Ovarian Cancer 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Surgery 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Relapse 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Drug Resistance 8. Adolescent 13-18 years 9. Gestational Trophoblastic Neoplasia
Provide patient population that should be included in the study
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Surgery 5. Young Adult 19-24 years 6. Epithelial Tumor Of Ovary 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Interval debulking surgery for advanced epithelial ovarian cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Surgery 5. Young Adult 19-24 years 6. Malignant Epithelial Ovarian Carcinoma 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Localization techniques for guided surgical excision of non‐palpable breast lesions
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Lesion Of Breast 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer
1. Aged 80 and over 80+ years 2. Ovarian Cancer 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Laparotomy 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Malignant Tumor Of Oropharynx 10. Malignant Tumor Of Oral Cavity 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Chemotherapy 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Cancer
Provide patient population that should be included in the study
Stapler versus scalpel resection followed by hand‐sewn closure of the pancreatic remnant for distal pancreatectomy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pancreatitis 6. Aged 65-79 years
Provide patient population that should be included in the study
Levomepromazine for nausea and vomiting in palliative care
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Vomiting 5. Young Adult 19-24 years 6. Palliative Care 7. Nausea 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Haloperidol for the treatment of nausea and vomiting in palliative care patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Vomiting 5. Young Adult 19-24 years 6. Palliative Care 7. Nausea 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Chemotherapy for advanced non‐small cell lung cancer in the elderly population
1. Aged 80 and over 80+ years 2. Non-small cell lung cancer stage III 3. Non-small cell lung cancer stage IV 4. Aged 65-79 years
Provide patient population that should be included in the study
Acupuncture for cancer pain in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cancer Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
High‐dose chemotherapy and autologous haematopoietic stem cell rescue for children with high‐risk neuroblastoma
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Young Adult 19-24 years 5. Birth to 1 mo 6. Neuroblastoma 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Sarcoma Of Soft Tissue 5. Infant 1 to 23 mo 6. Ewing's Sarcoma Of Bone 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Osteosarcoma Of Bone 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral tapentadol for cancer pain
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cancer Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Nutritional support in children and young people with cancer undergoing chemotherapy
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Chemotherapy 4. Infant 1 to 23 mo 5. Young Adult 19-24 years 6. Birth to 1 mo 7. Radiotherapy 8. Adolescent 13-18 years 9. Cancer
Provide patient population that should be included in the study
Multidisciplinary rehabilitation after primary brain tumour treatment
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Primary Malignant Neoplasm Of Brain
Provide patient population that should be included in the study
Spinal cord stimulation for cancer‐related pain in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Cancer Pain 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Taxane‐containing regimens for metastatic breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Metastatic breast cancer 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacological treatments for fatigue associated with palliative care
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Fatigue 6. Palliative Care 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Difficulty Swallowing 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Dysphagia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Neuroblastoma 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for cough in cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Cough 7. Cancer
Provide patient population that should be included in the study
Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Skin melanoma 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Laxatives for the management of constipation in people receiving palliative care
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Palliative Care 10. Constipation 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Laetrile treatment for cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Cancer
Provide patient population that should be included in the study
Buprenorphine for treating cancer pain
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Cancer Pain 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Chewing gum for postoperative recovery of gastrointestinal function
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Procedure On Abdomen 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Conservative interventions for preventing clinically detectable upper‐limb lymphoedema in patients who are at risk of developing lymphoedema after breast cancer therapy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Breast Cancer 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Hepatocellular carcinoma 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Disorder Of Thorax 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Non-small cell lung cancer 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Dance/movement therapy for improving psychological and physical outcomes in cancer patients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Cancer
Provide patient population that should be included in the study
Follow‐up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Cervical Intraepithelial Neoplasia Grade 1 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Minimally invasive surgery versus open surgery for the treatment of solid abdominal and thoracic neoplasms in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Neoplasm Of Intra-abdominal Organs 6. Neoplasm Of Intrathoracic Organs 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Chemotherapy for children with medulloblastoma
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Medulloblastoma 5. Young Adult 19-24 years 6. Birth to 1 mo 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Cervical Cancer 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Premalignant gastric lesion 6. Aged 65-79 years
Provide patient population that should be included in the study
Droperidol for treatment of nausea and vomiting in palliative care patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Vomiting 5. Young Adult 19-24 years 6. Palliative Care 7. Nausea 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Non-small cell lung cancer 9. Birth to 1 mo 10. Advanced Cancer 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Febrile Neutropenia 8. Young Adult 19-24 years 9. Chemotherapy-induced Neutropenia 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Cancer
Provide patient population that should be included in the study
High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Cervical Cancer 5. Young Adult 19-24 years 6. Advanced Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Codeine, alone and with paracetamol (acetaminophen), for cancer pain
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Cancer Pain 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Adolescent 13-18 years 6. Cancer
Provide patient population that should be included in the study
Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Kaposi's sarcoma 5. Young Adult 19-24 years 6. HIV infection 7. Aged 65-79 years
Provide patient population that should be included in the study
Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Prostate Cancer 6. Advanced Cancer 7. Aged 65-79 years
Provide patient population that should be included in the study
Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain
1. Cancer Pain
Provide patient population that should be included in the study
Surgical treatment of stage IA2 cervical cancer
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Cervical Cancer 4. Young Adult 19-24 years 5. International Federation Of Gynecology And Obstetrics Cervical Cancer (figo Cc) Stage Ia2 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)
1. Aged 80 and over 80+ years 2. Breast Cancer 3. Aged 65-79 years
Provide patient population that should be included in the study
Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Oligoastrocytoma 6. Aged 65-79 years 7. Anaplastic oligodendroglioma 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Adjuvant chemotherapy for advanced endometrial cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Endometrial cancer stage III 4. Middle Aged 45-64 years 5. Endometrial cancer stage IV 6. Surgery 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Medically assisted nutrition for adult palliative care patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Palliative Care 6. Nutritional Support 7. Aged 65-79 years
Provide patient population that should be included in the study
Laparoscopic versus open total mesorectal excision for rectal cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Rectal Cancer 6. Aged 65-79 years
Provide patient population that should be included in the study
Surgical interventions for high‐grade vulval intraepithelial neoplasia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Vulval Intraepithelial Neoplasia Grade 3 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases
1. Aged 80 and over 80+ years 2. Brain Metastasis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Primary Malignant Neoplasm 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Resection versus other treatments for locally advanced pancreatic cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Pancreatic cancer 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
De‐escalation treatment protocols for human papillomavirus‐associated oropharyngeal squamous cell carcinoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Human Papilloma Virus Infection 10. Oropharyngeal Cancer 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Exenterative surgery for recurrent gynaecological malignancies
1. Neoplasm Of Female Genital Organ 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Recurrent Cancer 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Combination versus sequential single agent chemotherapy for metastatic breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Metastatic breast cancer 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Chemotherapy versus best supportive care for extensive small cell lung cancer
1. Aged 80 and over 80+ years 2. Small Cell Carcinoma Of Lung 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Post‐operative radiotherapy for ductal carcinoma in situ of the breast
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Ductal Carcinoma In Situ 5. Young Adult 19-24 years 6. Breast Cancer 7. Aged 65-79 years
Provide patient population that should be included in the study
Patient‐reported outcome measures for follow‐up after gynaecological cancer treatment
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Chemotherapy 4. Middle Aged 45-64 years 5. Surgery 6. Young Adult 19-24 years 7. Gynaecological cancer 8. Radiotherapy 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Ovarian epithelial cancer 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Febrile Neutropenia 6. Young Adult 19-24 years 7. Bone marrow transplant disorder 8. Chemotherapy-induced Neutropenia 9. Adolescent 13-18 years 10. Cancer
Provide patient population that should be included in the study
Laparoscopically assisted radical vaginal hysterectomy versus radical abdominal hysterectomy for the treatment of early cervical cancer
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Cervical Cancer 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Perioperative nutrition interventions for women with ovarian cancer
1. Aged 80 and over 80+ years 2. Ovarian Cancer 3. Perioperative Care 4. Adult 19-44 years 5. Middle Aged 45-64 years 6. Surgery 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Cervico‐thoracic or lumbar sympathectomy for neuropathic pain and complex regional pain syndrome
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Complex Regional Pain Syndrome 5. Young Adult 19-24 years 6. Neuropathic Pain 7. Aged 65-79 years
Provide patient population that should be included in the study
Psychosocial interventions for patients with head and neck cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Head And Neck Cancer 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Maintenance chemotherapy for ovarian cancer
1. Aged 80 and over 80+ years 2. Ovarian Cancer 3. Adult 19-44 years 4. Chemotherapy 5. Middle Aged 45-64 years 6. Surgery 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Febrile Neutropenia 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Middle Aged 45-64 years 10. Young Adult 19-24 years 11. Chemotherapy-induced Neutropenia 12. Bone marrow transplant disorder 13. Cancer
Provide patient population that should be included in the study
Interventions for cutaneous Bowen's disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Bowen's disease 6. Precancerous skin lesion 7. Aged 65-79 years
Provide patient population that should be included in the study
Interferon alpha for the adjuvant treatment of cutaneous melanoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Skin melanoma 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Effectiveness and cost‐effectiveness of home palliative care services for adults with advanced illness and their caregivers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Critical Illness 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Ovarian epithelial cancer 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Fibrin glue instillation under skin flaps to prevent seroma‐related morbidity following breast and axillary surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Surgery 5. Young Adult 19-24 years 6. Breast Cancer 7. Aged 65-79 years
Provide patient population that should be included in the study
Sequencing of chemotherapy and radiotherapy for early breast cancer
1. Breast Cancer
Provide patient population that should be included in the study
Temozolomide for high grade glioma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. High Grade Glioma 8. Young Adult 19-24 years 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Megestrol acetate for treatment of anorexia‐cachexia syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Cachexia 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Pre‐treatment surgical para‐aortic lymph node assessment in locally advanced cervical cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Carcinoma Of Cervix 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Multidimensional rehabilitation programmes for adult cancer survivors
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Adolescent 13-18 years 5. Cancer
Provide patient population that should be included in the study
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Malignant Mixed Mullerian Tumor Of Uterus 6. Aged 65-79 years
Provide patient population that should be included in the study
Chemotherapy for metastatic and recurrent cervical cancer
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Cervical Cancer 4. Young Adult 19-24 years 5. Cervix cancer metastatic 6. Recurrent Cancer 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for reducing anxiety in women undergoing colposcopy
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Colposcopy 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Ovarian Germ Cell Neoplasm Malignant 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Chemotherapy and surgery versus surgery alone in non‐small cell lung cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Non-small cell lung cancer 6. Aged 65-79 years
Provide patient population that should be included in the study
Topical anti‐inflammatory treatments for eczema: network meta‐analysis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Eczema 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Non‐invasive high‐frequency ventilation in newborn infants with respiratory distress
1. Birth to 1 mo 2. Respiratory Distress
Provide patient population that should be included in the study
Oral killed cholera vaccines for preventing cholera
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical and oral steroids for otitis media with effusion (OME) in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Otitis Media with Effusion
Provide patient population that should be included in the study
Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Birth to 1 mo
Provide patient population that should be included in the study
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Different antibiotic treatments for group A streptococcal pharyngitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Streptococcus Pyogenes Infection 10. Pharyngitis 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Ventilation tubes (grommets) for otitis media with effusion (OME) in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Otitis Media with Effusion 4. Infant 1 to 23 mo
Provide patient population that should be included in the study
Antibiotics for acute otitis media in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Acute Otitis Media 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Methylxanthine for the prevention and treatment of apnea in preterm infants
1. Birth to 1 mo 2. Preterm Infant
Provide patient population that should be included in the study
Anti‐seizure medications for neonates with seizures
1. Neonate 2. Birth to 1 mo 3. Seizure
Provide patient population that should be included in the study
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Birth to 1 mo 4. Respiratory Syncytial Virus Infection
Provide patient population that should be included in the study
Immunomodulatory interventions for focal epilepsy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Focal epilepsy 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Higher versus lower sodium intake for preterm infants
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant
Provide patient population that should be included in the study
Superoxide dismutase for bronchopulmonary dysplasia in preterm infants
1. Birth to 1 mo 2. Very Low Birth Weight Infant 3. Preterm Infant
Provide patient population that should be included in the study
Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants
1. Birth to 1 mo 2. Preterm Infant
Provide patient population that should be included in the study
Psychological interventions for depression in adolescent and adult congenital heart disease
1. Congenital Heart Disease 2. Depression 3. Adolescent 13-18 years
Provide patient population that should be included in the study
Musical and vocal interventions to improve neurodevelopmental outcomes for preterm infants
1. Birth to 1 mo 2. Hospitalization 3. Preterm Infant
Provide patient population that should be included in the study
Breastfeeding or breast milk for procedural pain in neonates
1. Term infant (37-41 weeks) 2. Procedural Pain 3. Birth to 1 mo 4. Preterm Infant
Provide patient population that should be included in the study
Specific psychological therapies versus other therapies or no treatment for severe and enduring anorexia nervosa
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Anorexia Nervosa 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Acute Otitis Media 5. Adolescent 13-18 years
Provide patient population that should be included in the study
High flow nasal cannula for respiratory support in term infants
1. Birth to 1 mo
Provide patient population that should be included in the study
Vocabulary interventions for second language (L2) learners up to six years of age
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Second language learner
Provide patient population that should be included in the study
Perioperative glycaemic control for people with diabetes undergoing surgery
1. Type 2 Diabetes Mellitus 2. Type 1 Diabetes Mellitus
Provide patient population that should be included in the study
Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant
Provide patient population that should be included in the study
Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants
1. Birth to 1 mo 2. Neonatal Respiratory Distress Syndrome 3. Preterm Infant
Provide patient population that should be included in the study
Continuous positive airway pressure (CPAP) for apnoea of prematurity
1. Apnea of prematurity 2. Birth to 1 mo 3. Preterm Infant
Provide patient population that should be included in the study
Vedolizumab for induction and maintenance of remission in Crohn's disease
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Crohn's Disease 5. Middle Aged 45-64 years 6. Crohn's Disease In Remission 7. Young Adult 19-24 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Mobile phone‐based interventions for improving contraception use
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Contraception 5. Adolescent 13-18 years